Telmisartan 80mg Non-responder Trial

Overview

If a patient cannot have his or her blood pressure controlled with telmisartan 80 mg, an antihypertensive drug from different class should be started concomitantly. In the Japanese 3×3 factorial trial of telmisartan and hydrochlorothiazide in essential hypertension patients whose diastolic blood pressure (DBP) are equal or more than 95 mmHg, the DBP control rate (less than 90 mmHg) after 8 weeks treatment of the telmisartan 80 mg monotherapy group (66 patients) was 41.5%. There should be medical needs of the telmisartan 80 mg and amlodipine 5 mg fixed dose combination because some patients cannot have his or her blood pressure controlled with telmisartan 80 mg. Thus, this clinical trial is being conducted to evaluate the antihypertensive effect and safety of a fixed-dose combination (FDC) drug of 2 antihypertensive agents with different pharmacological effects, telmisartan 80 mg and amlodipine 5 mg (T80/A5 mg), compared with telmisartan 80 mg (T80 mg) monotherapy in Japanese patients with essential hypertension who fail to respond adequately to treatment with the maximum dose of telmisartan 80 mg monotherapy. In this trial, a multi-centre, randomised, double-blind, double-dummy, active-controlled, parallel group comparison method is employed.

Full Title of Study: “An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg+ Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 80 mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg Monotherapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double
  • Study Primary Completion Date: June 2011

Interventions

  • Drug: Telmisartan and amlodipine
    • Telmisartan 80 mg and amlodipine 5 mg once a daily
  • Drug: Telmisartan
    • 80 mg once a daily

Arms, Groups and Cohorts

  • Experimental: Telmisartan and amlodipine FDC
    • once a daily
  • Active Comparator: Telmisartan monotherapy
    • once a daily

Clinical Trial Outcome Measures

Primary Measures

  • Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough
    • Time Frame: Baseline, 8 weeks
    • Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients’ eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing

Secondary Measures

  • Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough
    • Time Frame: Baseline, 8 weeks
    • Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients’ eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
  • Seated DBP Control Rate at Trough
    • Time Frame: 8 weeks
    • DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
  • Seated SBP Control Rate at Trough
    • Time Frame: 8 weeks
    • SBP control rate: The rate of patients with controlled seated SBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
  • Seated DBP Response Rate at Trough
    • Time Frame: 8 weeks
    • DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (<90 mmHg and/or reduction from reference baseline ≥10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
  • Seated SBP Response Rate at Trough
    • Time Frame: 8 weeks
    • SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (<140 mmHg and/or reduction from reference baseline ≥20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
  • Seated Blood Pressure (BP) Normalisation at Trough
    • Time Frame: 8 weeks
    • Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing

Participating in This Clinical Trial

Inclusion Criteria

  • Essential hypertensive patients – If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be >=90 and >=114 mmHg – If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114 mmHg – Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion. Exclusion criteria:

  • Patients taking 3 or more antihypertensive drugs at signing the informed consent form – Patients with known or suspected secondary hypertension – Patients with clinically relevant cardiac arrhythmia – Congestive heart failure with New York Heart Association (NYHA) functional class III-IV – Patients with recent cardiovascular events – Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form – Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy – Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors – Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs – Patients with hepatic and/or renal dysfunction – Pre-menopausal women who are nursing or pregnant

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Boehringer Ingelheim
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Boehringer Ingelheim, Study Chair, Boehringer Ingelheim

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.